142404-82-8

Basic information

• Product Name: 2-ACETAMIDO-4-METHYL-5-BROMOPYRIDINE
• Synonyms: 2-ACETYLAMINO-5-BROMO-4-METHYLPYRIDINE;2-ACETAMIDO-4-METHYL-5-BROMOPYRIDINE;2-ACETAMIDO-5-BROMO-4-PICOLINE;N-(5-BROMO-4-METHYL-PYRIDIN-2-YL)-ACETAMIDE;2-Acetamido-5-bromo-gamma-picoline;2-Acetylamino-5-bromo-4-methylpyridine ,97%;2-Acetamido-5-bromo-4-methylpyridine;Acetamide,N-(5-bromo-4-methyl-2-pyridinyl)-
• CAS NO: 142404-82-8
• Molecular Formula: C₈H₉BrN₂O
• Molecular Weight: 229.07
• Product Categories: Pyridine;C7 and C8Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines
• Mol File: 142404-82-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 151-155 °C(lit.)
• Boiling Point: 372.5 °C at 760 mmHg
• Flash Point: 179.1 °C
• Appearance: /
• Density: 1.545
• Vapor Pressure: 9.6E-06mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Chloroform
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: 2-ACETAMIDO-4-METHYL-5-BROMOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ACETAMIDO-4-METHYL-5-BROMOPYRIDINE(142404-82-8)
• EPA Substance Registry System: 2-ACETAMIDO-4-METHYL-5-BROMOPYRIDINE(142404-82-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41-42/43
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 142404-82-8(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

2-Acetamido-5-bromo-4-methylpyridine is used in the continuous exothermix process of nitration.

InChI:InChI=1/C8H9BrN2O/c1-5-3-8(11-6(2)12)10-4-7(5)9/h3-4H,1-2H3,(H,10,11,12)

Upstream product

• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 108-24-7 acetic anhydride 
• 5327-32-2 2-acetylamino-4-methylpyridine 
• 695-34-1 2-Amino-4-methylpyridine 
• 864830-16-0 5-bromo-2-fluoro-4-methyl-pyridine 
• 124-42-5 acetamidine hydrochloride 

Downstream Products

• 5327-32-2 2-acetylamino-4-methylpyridine 
• 100367-40-6 2-amino-3-nitro-4-methyl-5-bromopyridine 
• 864953-39-9 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogen phosphate 
• 1392514-39-4 C₂₅H₂₄ClN₇O₄ 
• 917918-81-1 2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine 
• 917918-82-2 C₁₁H₁₅N₃O₄ 
• 1392514-36-1 C₂₁H₁₈ClN₅O₄S 
• 1392514-37-2 C₃₁H₂₈ClN₇O₄S 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 884495-14-1 5-bromo-2-methoxy-4-methyl-3-nitropyridine 
• 228410-90-0 2-hydroxy-5-bromo-4-methyl-3-nitropyridine 
• 364046-14-0 4-[(2-di-N,N-methylamino)vinyl]-2-methoxy-3-nitropyridine 
• 701213-36-7 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-ethane-1,2-dione 
• 1171975-45-3 2-(acetylamino)-5-(4-t-butylphenyl)-4-picoline 

Relevant articles and documents

The reaction of some brominated aminopicolines with acetic anhydride and with copper(I) cyanide

-

Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies

The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.

SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1 R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.